In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents.
about
Induction of stemlike cells with fibrogenic properties by carbon nanotubes and its role in fibrogenesisLuciferase reporter cells as a platform to detect SMAD-dependent collagen productionPreclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and PerspectiveRole of the lesion scar in the response to damage and repair of the central nervous systemPredicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysisFocus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art.Three-dimensional paper-based model for cardiac ischemiaShear stress-induced volume decrease in C11-MDCK cells by BK-alpha/beta4.Lipopolysaccharide and hypoxia significantly alters interleukin-8 and macrophage chemoattractant protein-1 production by human fibroblasts but not fibrosis related factors.Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo.Silencing CD36 gene expression results in the inhibition of latent-TGF-beta1 activation and suppression of silica-induced lung fibrosis in the rat.Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis.An in vitro model for the pro-fibrotic effects of retinoids: mechanisms of actionOrgan printing: tissue spheroids as building blocks.Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation.The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well.Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A3 adenosine receptor antagonists and partial agonists.Potential nephroprotective effects of the Chinese herb Angelica sinensis against cisplatin tubulotoxicity.Localized expression of tenascin in systemic sclerosis-associated pulmonary fibrosis and its regulation by insulin-like growth factor binding protein 3.Platelet-rich plasma (PRP) impairs the craniofacial bone repair associated with its elevated TGF-β levels and modulates the co-expression between collagen III and α-smooth muscle actin.Tissue spheroid fusion-based in vitro screening assays for analysis of tissue maturation.A sensitive short-term evaluation of antifibrotic effects using newly established type I collagen reporter transgenic rats.A CD36 synthetic peptide inhibits silica-induced lung fibrosis in the mice.In vitro anti-fibrotic activities of herbal compounds and herbs.Duchenne muscular dystrophy fibroblast nodules: a cell-based assay for screening anti-fibrotic agents.Test of Antifibrotic Drugs in a Cellular Model of Fibrosis Based on Muscle-Derived Fibroblasts from Duchenne Muscular Dystrophy Patients.Lysophosphatidylcholine activates the Akt pathway to upregulate extracellular matrix protein production in human aortic valve cells.MicroRNA-21-5p mediates TGF-β-regulated fibrogenic activation of spinal fibroblasts and the formation of fibrotic scars after spinal cord injury.Neurotrophin 3 upregulates proliferation and collagen production in human aortic valve interstitial cells: a potential role in aortic valve sclerosis.Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype.Directed fusion of cardiac spheroids into larger heterocellular microtissues enables investigation of cardiac action potential propagation via cardiac fibroblasts.An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines.Fibrotic microtissue array to predict anti-fibrosis drug efficacy.
P2860
Q23921932-01E5FC5A-1FC5-4F64-995D-788688F278E2Q23923550-D5F91F29-836E-4ED1-BAC9-DC98E8720FF8Q26768482-25637628-4984-470B-9BEF-344E2A62F7EDQ26999096-CB4F278D-486A-4795-8039-9F121B4B2732Q28477748-0A0BC6E1-92A6-48A7-AAC9-25BFE3C900E0Q33518024-EECF371C-FA35-4CFF-A67F-E5248D39722EQ33934409-01341DD2-FBE1-4DCA-9736-01B7F95543D7Q34149593-B5C7EA4A-D218-4651-9C3B-21D9E25788C1Q35835370-3B17AFE3-C840-45CE-95A6-9D810839413AQ35908995-DEB25457-5DA5-42EA-B0E8-5128943F6B5DQ37176705-6B147460-16C8-4C19-BBB5-43F7580D9183Q37233740-C2564AEC-CBA6-4CB6-9983-ABE42D441DDCQ37306427-6D30DDC2-C3D1-4370-91F8-AAF25E3FDE0EQ37337864-B37A04E7-E35F-436D-BFD8-110E22EB3C79Q37379489-8AB91C88-DC43-4384-BAFD-EFDE050D4FF5Q37386506-08AE8332-F146-4E57-BA89-540FA0655237Q37434404-4881C7C0-3667-45E4-9B93-6656BEA5DCD6Q37637798-E63277D5-D343-46BC-A0BC-4E24FB96B1D8Q38930073-D20776B3-3E2C-4471-8B2B-F34709F233D6Q39894766-3724E534-C56C-438D-A6F5-D320928141DEQ39953619-E1F62DBB-2BF8-470D-BC8C-029DB9CBD6DFQ42412825-FE867943-94EA-476C-97A5-749E65FE8AD8Q42957610-FC3470C9-A565-4040-AAD7-06999EEE0D90Q43199907-87EDE64A-A300-4761-B020-48CEDAD5AE32Q43605198-58ECC732-624F-4478-8B50-0EDA8872F935Q44110265-E6FE1B5A-40D3-4D74-BB9C-48C054DB4362Q50079567-86912962-BBAA-4A82-8E76-D3CC22655C58Q50205280-EEF6D5C1-66D8-4FFF-9E7D-3DA5311444BBQ50327593-04724F11-5E23-400D-BD5A-ABB538FAB5B4Q51081685-91CB0FC5-F64F-4E20-9F39-DB8C85235C69Q52655048-68A621BF-CBCF-4CE2-83B1-D8ADA3B44597Q52715170-311B5CC5-91C9-4F7D-9AE3-85EBD94D55A5Q55073347-3DFA9100-7BF4-4BE4-AD37-28BFF8B4A641Q55221753-48449882-8D87-49AD-8BE6-4974B1CD8D0D
P2860
In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of antifibrotic agents.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
In vitro models of TGF-beta-in ...... eening of antifibrotic agents.
@en
type
label
In vitro models of TGF-beta-in ...... eening of antifibrotic agents.
@en
prefLabel
In vitro models of TGF-beta-in ...... eening of antifibrotic agents.
@en
P2093
P2860
P1476
In vitro models of TGF-beta-in ...... eening of antifibrotic agents.
@en
P2093
Javier Lucio-Cazana
Jill T Norman
Shashi Shrivastav
P2860
P304
P356
10.1152/AJPRENAL.00379.2006
P577
2007-05-09T00:00:00Z